ESPERION THERAPEUTICS INC. - COMMON STOCK

1,5200

12-марта-25 15:45:02

15 мин. задержка

Акции

-0,0300

-1,94%

Сегодняшний диапазон

1,5100 - 1,5800

ISIN

N/A

Источник

NASDAQ

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

07 ноя 2024 05:00:00 Источник Nasdaq GlobeNewswire
Esperion to Participate in Upcoming Jefferies London Healthcare Conference

04 ноя 2024 07:00:25 Источник Nasdaq GlobeNewswire
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

31 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion to Report Third Quarter 2024 Financial Results on November 7

24 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

02 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

25 сен 2024 15:30:00 Источник Nasdaq GlobeNewswire
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

05 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

03 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

26 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

12 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

07 авг 2024 15:30:00 Источник Nasdaq GlobeNewswire
Esperion to Report Second Quarter 2024 Financial Results on August 12

25 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion to Participate in Upcoming BTIG Biotech Conference

24 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

16 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

28 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire
Esperion to Participate in Upcoming June Investor Conferences

23 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

22 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

20 май 2024 05:00:00 Источник Nasdaq GlobeNewswire
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

14 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

10 май 2024 15:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.